Castle Biosciences Advances Barrett’s Risk Testing With TissueCypher
Friendswood, Texas, U.S., September 28, 2026 Castle Biosciences has announced new clinical evidence demonstrating how its TissueCypher® Barrett’s Esophagus...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Friendswood, Texas, U.S., September 28, 2026 Castle Biosciences has announced new clinical evidence demonstrating how its TissueCypher® Barrett’s Esophagus...
San Francisco, California, September 15, 2026 Debut has announced the development of a new biotechnology-derived ingredient for hyperpigmentation, marking...
Phoenix, Arizona, September 15, 2026 Castle Biosciences has announced findings from a new decision-modeling study showing that its TissueCypher...
FRIENDSWOOD, Texas, July 14, 2026 Castle Biosciences, Inc. has announced that its AdvanceAD-Txâ„¢ test has received assay approval from...
FRIENDSWOOD, Texas, June 25, 2026 Castle Biosciences announced the publication of a prospective multicenter study in Dermatology and Therapy...
BOULDER, Colo., June 16, 2026 Edgewise Therapeutics has announced positive top-line results from the 12-week Phase 2 CIRRUS-HCM trial...
FRIENDSWOOD, Texas, June 16, 2026 Castle Biosciences has announced that its TissueCypher® Barrett’s Esophagus Test has surpassed 100,000 clinical...
FRIENDSWOOD, Texas, May 12, 2026 Castle Biosciences announced that its AdvanceAD-Txâ„¢ gene expression profiling test received the prestigious 2026...
DUBLIN, Ireland, May 12, 2026 Alkermes announced positive topline results from the pivotal REVITALYZ Phase 3 clinical trial evaluating...
FRIENDSWOOD, TEXAS, May 04, 2026 Castle Biosciences has announced the presentation of new clinical data at Digestive Disease Week...
